Comparativa de alemtuzumab y Rebif ® Eficacia en la esclerosis múltiple, estudiar dos

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2007

Este artículo no está incluido en ninguna revisión sistemática

Este artículo es parte de los siguientes hilos de publicación
  • CARE-MS 2 [Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two] (22 documentos)
Cargando información sobre las referencias
The purpose of this study was to establish the efficacy and safety of two different doses of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous interferon beta-1a (Rebif®). The study enrolled participants who had received an adequate trial of disease-modifying therapies but experienced at least 1 relapse during prior treatment, and who met a minimum severity of disease as measured by magnetic resonance imaging (MRI). Participants had monthly laboratory tests and comprehensive testing every 3 months.
Epistemonikos ID: f5df3487e38212072b8dc7b6f64212e091cf1eb5
First added on: Oct 03, 2014